Gerald Andriole, MD
388 posts
Gerald Andriole, MD
@uropro
Chief Medical Officer, Prostatype Genomics
Katılım Ekim 2009
948 Takip Edilen1.8K Takipçiler
Finally an improved biopsy needle! #Xagasurgical #AUA2026 #Booth2863
Better targeting and reduced bacterial transfer
English
Gerald Andriole, MD retweetledi
A toast 🥂 to the 50th Anniversary of the Winter Urologic Forum! 💫
Always a great meeting!
@ColumbiaUrology @UCDavisUrology
Vanderbilt Urology
English
Gerald Andriole, MD retweetledi
Phase 1 study evaluates bone metastasis resolution with SYNC-T therapy SV-102. @uropro @ProstatypeAB joins @zklaassen_md @GACancerCenter SYNC-T therapy SV-102 for metastatic prostate cancer. The treatment combines one-minute cryolysis of tumor tissue with immediate infusion of a four-component immunoadjuvant to generate tumor-specific T cell responses. #WatchNow > bit.ly/3MuSxKr
English
Adam Cole @pathnetlab at @UrologyUS winter meeting showing off near-future future "pathology porn": 3D multimodal analysis of full uncut biopsy cores, with AI weighing in 🤯
English
Prostatype P-score demonstrated superb risk classification of Prostate Cancer in a diverse US population. Very useful tool for men considering Active Surveillance and the intensity of surveillance. Low risk men had no PCSM! @nature.com/pcan/
English
Phase 1 study evaluates bone metastasis resolution with SYNC-T therapy SV-102. @uropro @ProstatypeAB joins @zklaassen_md @GACancerCenter SYNC-T therapy SV-102 for metastatic prostate cancer. The treatment combines one-minute cryolysis of tumor tissue with immediate infusion of a four-component immunoadjuvant to generate tumor-specific T cell responses. #WatchNow > bit.ly/3MuSxKr
English
Gerald Andriole, MD retweetledi
Thank you #SUO25. We were proud to share Phase 1 SYNC-T data showing 54% of metastatic prostate cancer patients had complete resolution of bone metastases and favorable tolerability.
SYNC-T is now being studied for mCRPC in the Phase 2 LEGION-100 trial.
Details: bit.ly/48jYaU5
English
Gerald Andriole, MD retweetledi
#SUO25 @uropro presents SYNC-T SV-102 for mPCa
🧬 Image-guided intratumoral immunotherapy targeting 4 immune axes
👥 n=15 (Phase 1) | post-ARPI or hormone-declined | bone mets in 87%
🔹 ORR: 87% | CR: 53%
🔹 Bone mets resolved in 7/13 pts incl. >50 lesions in 1 case
🛡️ 95% Grade 1–2 AEs | no Gr 4/5
✅ Early signal for durable, systemic immunity via local delivery
@UroToday @UroOnc
English
Gerald Andriole, MD retweetledi
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
- 87% ORR
- 53% CR
- 100% DCR
- 14.2 months rPFS
- 80% survival after 17.2 month median follow-up
globenewswire.com/news-release/2…
English
Gerald Andriole, MD retweetledi
Stop by the Syncromune booth at #ASCO25 to learn more about our LEGION-100 Phase 2a trial of SYNC-T Therapy SV-102 for #mCRPC. Now enrolling and recruiting clinical trial sites. #LEGION100 #ProstateCancer
English
Gerald Andriole, MD retweetledi
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting #ASCO25 globenewswire.com/news-release/2…
English
Gerald Andriole, MD retweetledi
So inspired to be collaborating with an incredible team of experts in bladder cancer. Excited for the impactful work we’ll do together transforming early detection!
prn.to/3yI2PQy
@UroCancerMD @pcvblack @SimaPorten @siadaneshmand @ctleeuro @garysteinbergmd @ylotan
English
Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market prostatypegenomics.com/cision/A205D66…
English
Prostatype Genomics AB US subsidiary Prostatype Genomics, Inc. has been accredited by the CAP (College of American Pathologists) Laboratory Accreditation Program!
English
Dr. Gerald Andriole presented Prostatype Genomic Classifier's ability, with a significant AUC of .88 (Gleason score ≥4+3and/or pT3), to predict adverse pathology at RP.
📷
English
Gerald Andriole, MD retweetledi
Gordo ranks area hoops: Cloud forms over Illinois, SLU gets huge boost dlvr.it/T0qfqh
English
Gerald Andriole, MD retweetledi
#FOCAL2023 starts TOMORROW! Make sure to follow all of our awesome faculty!
@arvinkgeorge @AbhinavSidana @Freddie_Hamdy @DrJohnMDiBi @uropro @LetDdiceFlyHigh @ezebecher @DrSteveCanfield @peterchiu_uro @ChughtaiMD @BehfarEhdaieMD @FryeUroOnc @gupta_go @amy_krambeck @fleauxdoc @oncostan @lissmike @RaisBahrami @Rowe_NuclearMed @TaimurShah @DrilyaSobol1 @Dr_sprenkle @tanejauro @radiolobt @vermasadhna @vourganti @Dr_KevinZorn
English